{"protocolSection": {"identificationModule": {"nctId": "NCT00624442", "orgStudyIdInfo": {"id": "CY 1121"}, "organization": {"fullName": "Cytokinetics", "class": "INDUSTRY"}, "briefTitle": "A Study of CK-1827452 Infusion in Stable Heart Failure", "officialTitle": "A Phase II, Multi Center, Double-Blind, Randomized, Placebo Controlled, Dose-Escalation, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CK-1827452 in Patients With Stable Heart Failure"}, "statusModule": {"statusVerifiedDate": "2021-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-04"}, "primaryCompletionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-12-21", "studyFirstSubmitQcDate": "2008-02-19", "studyFirstPostDateStruct": {"date": "2008-02-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-02-28", "resultsFirstSubmitQcDate": "2010-07-16", "resultsFirstPostDateStruct": {"date": "2010-08-16", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-04-20", "lastUpdatePostDateStruct": {"date": "2021-05-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Cytokinetics", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will assess the safety, tolerability, and pharmacodynamics of CK-1827452 infusion in patients with stable heart failure."}, "conditionsModule": {"conditions": ["Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 45, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Cohort 1", "type": "EXPERIMENTAL", "description": "4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.", "interventionNames": ["Drug: CK-1827452", "Drug: Placebo"]}, {"label": "Cohort 2", "type": "EXPERIMENTAL", "description": "4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.", "interventionNames": ["Drug: CK-1827452", "Drug: Placebo"]}, {"label": "Cohort 3", "type": "EXPERIMENTAL", "description": "4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.", "interventionNames": ["Drug: Placebo", "Drug: CK-1827452"]}, {"label": "Cohort 4", "type": "EXPERIMENTAL", "description": "4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.", "interventionNames": ["Drug: CK-1827452", "Drug: Placebo"]}, {"label": "Cohort 5", "type": "EXPERIMENTAL", "description": "2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1.", "interventionNames": ["Drug: CK-1827452", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h", "armGroupLabels": ["Cohort 1"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h", "armGroupLabels": ["Cohort 1"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h", "armGroupLabels": ["Cohort 1", "Cohort 2"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h", "armGroupLabels": ["Cohort 2"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h", "armGroupLabels": ["Cohort 2"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h", "armGroupLabels": ["Cohort 4"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h", "armGroupLabels": ["Cohort 4"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h", "armGroupLabels": ["Cohort 4"]}, {"type": "DRUG", "name": "Placebo", "description": "IV infusion for 2 hours", "armGroupLabels": ["Cohort 1", "Cohort 2"]}, {"type": "DRUG", "name": "Placebo", "description": "IV infusion for 24 hours", "armGroupLabels": ["Cohort 3", "Cohort 4"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h", "armGroupLabels": ["Cohort 5"]}, {"type": "DRUG", "name": "Placebo", "description": "IV infusion for 72 hours", "armGroupLabels": ["Cohort 5"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h", "armGroupLabels": ["Cohort 5"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h", "armGroupLabels": ["Cohort 3"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h", "armGroupLabels": ["Cohort 3"]}, {"type": "DRUG", "name": "CK-1827452", "description": "IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h", "armGroupLabels": ["Cohort 3"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations", "description": "Pooled analysis of the echocardiographic measure systolic ejection time from echocardiograms taken at all timepoints. The systolic ejection time is the period during which the aortic valve is open and blood is flowing across the valve. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.", "timeFrame": "4 days"}, {"measure": "Change From Baseline of Fractional Shortening at Various CK-1827452 Plasma Concentrations", "description": "Pooled analysis of the echocardiographic measure fractional shortening from echocardiograms taken at all timepoints. Fractional shortening is the percentage of change from baseline in the left ventricular cavity dimension with systole. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.", "timeFrame": "4 days"}], "secondaryOutcomes": [{"measure": "CK-1827452 Maximum Observed Plasma Concentration (Cmax)", "description": "Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion", "timeFrame": "2 days"}, {"measure": "CK-1827452 Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUClast)", "description": "Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion", "timeFrame": "2 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n1. Patient is male, or female of non-childbearing potential (two years post-menopausal or surgically sterilized)\n2. Female patients must have a negative urine pregnancy test prior to entry into the study\n3. Patient is 18 years old or greater\n4. Patient has given signed informed consent\n5. Patient is considered to be in suitable health in the opinion of the investigator, as determined by:\n\n   * A pre-study physical examination with no clinical abnormalities which in the opinion of the investigator would preclude participation in the study other than physical symptoms or signs consistent with stable heart failure\n   * An electrocardiogram (ECG) with no abnormalities in the opinion of the investigator that would impair assessment of stopping criteria\n6. Patient has pre-study clinical laboratory findings that are within normal range, or if outside of the normal range, should not preclude participation in the study in the opinion of the investigator (see Exclusion Criteria, below, for exceptions)\n7. Patient has a documented diagnosis of heart failure with an ejection fraction of less than 40%\n8. Patient has been on a stable dose of a beta blocker and an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin II receptor blocker) for at least 4 weeks. If prescribed, diuretics must have been administered according to a consistent regimen for at least 4 weeks\n9. Patient is currently in sinus rhythm\n10. Patient has interpretable echocardiographic images on a screening echocardiogram\n\nExclusion Criteria\n\n1. Patient has been hospitalized for heart failure, myocardial infarction, coronary revascularization, or another cardiac indication within the last 6 weeks\n2. Patient has a current history of alcohol use which in the opinion of the investigator would preclude participation in the study\n3. Patient has a current history of drug abuse\n4. Patient has donated blood or blood products within 30 days prior to screening\n5. Patient has Canadian Cardiovascular Society (CCS) Class III or IV angina\n6. Patient has significant obstructive valvular disease or significant congenital heart disease\n7. Patient has had a valve replacement\n8. Patient is pacemaker dependent\n9. Patient is on chronic anti-arrhythmic therapy, with the exception of amiodarone\n10. Patient is currently taking, or has taken in the last 7 days, a CYP3A4 inhibitor or inducer medication\n11. Patient has a history of hypertrophic obstructive cardiomyopathy\n12. Patient weighs \\> 120 kg\n13. Patient has a supine resting systolic blood pressure \\< 95 mmHg after 3 minutes rest\n14. Patient has a supine resting heart rate \u2265 100 beats per minute after 3 minutes rest\n15. Patient has an Modification of Diet in Renal Disease (MDRD) estimate of Glomerular Filtration Rate (GFR) \u2264 35 ml/min/1.73 m2\n16. Patient has a potassium \\< 3.5 mEq/L or \\> 5.5 mEq/L\n17. Patient has a sodium \u2264 133 mEq/L\n18. Patient has a urea \\> 15 mmole/L\n19. Patient has a troponin I or T at screening that is detectable at the investigative site's clinical laboratory\n20. Patient has a hemoglobin \\< 11 gm/dL in males or \\< 10 gm/dL in females\n21. Patient has an alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALKP) or total bilirubin (TBILI) \\> 3 times the upper limit of normal\n22. Patient is, in the opinion of the investigator, not suitable to participate in the study\n23. Patient has participated in any clinical study with an investigational drug within three months prior to the first day of dosing with the exception of coronary stent studies Patient has ever received CK-1827452", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "University of California, San Diego Medical Center", "city": "San Diego", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Christiana Care Health Services, Inc.", "city": "Newark", "state": "Delaware", "zip": "19713", "country": "United States", "geoPoint": {"lat": 39.68372, "lon": -75.74966}}, {"facility": "Diagnostic Services Clinic", "city": "Tbilisi", "country": "Georgia", "geoPoint": {"lat": 41.69411, "lon": 44.83368}}, {"facility": "Russian Cardiological Research and Production Complex", "city": "Moscow", "zip": "121552", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Dzhanelidze Research Institute for Emergency Medical Care", "city": "St. Petersburg", "zip": "192242", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Almazov Federal Heart, Blood and Endocrinology Center", "city": "St. Petersburg", "zip": "194156", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "St. Petersburg State Medical University", "city": "St. Petersburg", "zip": "197089", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Castle Hill Hospital, University of Hull", "city": "Hull", "state": "England", "zip": "HU16 5JQ", "country": "United Kingdom", "geoPoint": {"lat": 53.7446, "lon": -0.33525}}, {"facility": "King's College Hospital", "city": "London", "state": "England", "zip": "SE5 9RS", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "St. George's Hospital", "city": "London", "state": "England", "zip": "SW17 ORE", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "St. Mary's Hospital & Imperial College", "city": "London", "state": "England", "zip": "W2 1LA", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Manchester Heart Centre, Manchester Royal Infirmary", "city": "Manchester", "state": "England", "zip": "M13 9WL", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "ICON Development Solutions", "city": "Manchester", "state": "England", "zip": "M15 6SH", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Wythenshawe Hospital", "city": "Manchester", "state": "England", "zip": "M23 9LT", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Northwick Park Hospital", "city": "Middlesex", "state": "England", "zip": "HA1 3UJ", "country": "United Kingdom", "geoPoint": {"lat": 51.53174, "lon": -0.26856}}, {"facility": "Ninewells Hospital and Medical School", "city": "Dundee", "state": "Scotland", "zip": "DD1 9SY", "country": "United Kingdom", "geoPoint": {"lat": 56.46913, "lon": -2.97489}}, {"facility": "BHF Cardiovascular Centre", "city": "Glasgow", "state": "Scotland", "zip": "G12 8TA", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}]}, "referencesModule": {"references": [{"pmid": "25951506", "type": "DERIVED", "citation": "Vu T, Ma P, Xiao JJ, Wang YM, Malik FI, Chow AT. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. J Clin Pharmacol. 2015 Nov;55(11):1236-47. doi: 10.1002/jcph.538. Epub 2015 Jul 14."}, {"pmid": "21856481", "type": "DERIVED", "citation": "Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011 Aug 20;378(9792):676-83. doi: 10.1016/S0140-6736(11)61126-4."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "The recruitment period was from April 2007 to January 2009.", "groups": [{"id": "FG000", "title": "Cohort 1", "description": "4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart."}, {"id": "FG001", "title": "Cohort 2", "description": "4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart."}, {"id": "FG002", "title": "Cohort 3", "description": "4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart."}, {"id": "FG003", "title": "Cohort 4", "description": "4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the sequence. Treatment periods occur at least 7 days apart."}, {"id": "FG004", "title": "Cohort 5", "description": "2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "comment": "One patient was discontinued after inadvertant overdose.", "numSubjects": "8"}, {"groupId": "FG002", "comment": "Two patients discontinued after meeting termination criteria during dosing.", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "comment": "Two patients discontinued after meeting termination criteria during dosing.", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Cohort 1", "description": "4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart."}, {"id": "BG001", "title": "Cohort 2", "description": "4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart."}, {"id": "BG002", "title": "Cohort 3", "description": "4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart."}, {"id": "BG003", "title": "Cohort 4", "description": "4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the sequence. Treatment periods occur at least 7 days apart."}, {"id": "BG004", "title": "Cohort 5", "description": "2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "10"}, {"groupId": "BG005", "value": "45"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "7"}, {"groupId": "BG005", "value": "30"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "3"}, {"groupId": "BG005", "value": "15"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59.0", "spread": "11.9"}, {"groupId": "BG001", "value": "56.0", "spread": "14.3"}, {"groupId": "BG002", "value": "62.0", "spread": "8.2"}, {"groupId": "BG003", "value": "52.6", "spread": "18.0"}, {"groupId": "BG004", "value": "57.0", "spread": "14.0"}, {"groupId": "BG005", "value": "57.5", "spread": "13.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "6"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "39"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "3"}]}]}, {"title": "Georgia", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "2"}]}]}, {"title": "Russian Federation", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "11"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "5"}, {"groupId": "BG005", "value": "29"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations", "description": "Pooled analysis of the echocardiographic measure systolic ejection time from echocardiograms taken at all timepoints. The systolic ejection time is the period during which the aortic valve is open and blood is flowing across the valve. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.", "populationDescription": "Pharmacodynamic Population. 4-way crossover design for cohorts 1-4 and 2-way crossover for cohort 5 requires multiple dosing events per participant. Also, multiple PK/PD assessments occur per dosing event.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "msec", "timeFrame": "4 days", "groups": [{"id": "OG000", "title": ">0-100 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}, {"id": "OG001", "title": ">100-200 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}, {"id": "OG002", "title": ">200-300 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}, {"id": "OG003", "title": ">300-400 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}, {"id": "OG004", "title": ">400-500 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}, {"id": "OG005", "title": ">500 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "27"}, {"groupId": "OG003", "value": "22"}, {"groupId": "OG004", "value": "17"}, {"groupId": "OG005", "value": "25"}]}], "classes": [{"title": "# of Echocardiographic Observations (no units)", "categories": [{"measurements": [{"groupId": "OG000", "value": "84", "spread": "0"}, {"groupId": "OG001", "value": "62", "spread": "0"}, {"groupId": "OG002", "value": "42", "spread": "0"}, {"groupId": "OG003", "value": "24", "spread": "0"}, {"groupId": "OG004", "value": "20", "spread": "0"}, {"groupId": "OG005", "value": "46", "spread": "0"}]}]}, {"title": "Ejection Fraction msec Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1", "spread": "4"}, {"groupId": "OG001", "value": "18", "spread": "4"}, {"groupId": "OG002", "value": "47", "spread": "5"}, {"groupId": "OG003", "value": "58", "spread": "6"}, {"groupId": "OG004", "value": "59", "spread": "6"}, {"groupId": "OG005", "value": "80", "spread": "5"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.8842", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7", "ciUpperLimit": "8"}, {"groupIds": ["OG001"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "10", "ciUpperLimit": "27"}, {"groupIds": ["OG002"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "47", "ciPctValue": "95", "ciLowerLimit": "38", "ciUpperLimit": "56"}, {"groupIds": ["OG003"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "58", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "46", "ciUpperLimit": "70"}, {"groupIds": ["OG004"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "47", "ciUpperLimit": "72"}, {"groupIds": ["OG005"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "71", "ciUpperLimit": "89"}, {"groupIds": ["OG000", "OG001", "OG002", "OG003", "OG004", "OG005"], "groupDescription": "All available concentration data are used in the model as a continuous variable.\n\np-value based on individual plasma concentration of CK-1827452 vs. corresponding systolic ejection time PD assessment (not binned based on plasma concentration)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis based on the following model: Change from baseline = Concentration + Baseline + Error, treating patients as random effect", "ciPctValue": "95"}]}, {"type": "PRIMARY", "title": "Change From Baseline of Fractional Shortening at Various CK-1827452 Plasma Concentrations", "description": "Pooled analysis of the echocardiographic measure fractional shortening from echocardiograms taken at all timepoints. Fractional shortening is the percentage of change from baseline in the left ventricular cavity dimension with systole. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.", "populationDescription": "Pharmacodynamic Population. 4-way crossover design for cohorts 1-4 and 2-way crossover for cohort 5 requires multiple dosing events per participant. Also, multiple PK/PD assessments occur per dosing event.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "4 days", "groups": [{"id": "OG000", "title": ">0-100 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}, {"id": "OG001", "title": ">100-200 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}, {"id": "OG002", "title": ">200-300 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}, {"id": "OG003", "title": ">300-400 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}, {"id": "OG004", "title": ">400-500 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}, {"id": "OG005", "title": ">500 ng/mL", "description": "Measurements pooled by plasma concentration of CK-1827452 at time of pharmacodynamic measure. Measurements at any dose level or timepoint could contribute to this bin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "21"}, {"groupId": "OG004", "value": "14"}, {"groupId": "OG005", "value": "23"}]}], "classes": [{"title": "# of Echocardiographic Observations (no units)", "categories": [{"measurements": [{"groupId": "OG000", "value": "81", "spread": "0"}, {"groupId": "OG001", "value": "56", "spread": "0"}, {"groupId": "OG002", "value": "37", "spread": "0"}, {"groupId": "OG003", "value": "23", "spread": "0"}, {"groupId": "OG004", "value": "17", "spread": "0"}, {"groupId": "OG005", "value": "44", "spread": "0"}]}]}, {"title": "Fractional Shortening Percent Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1", "spread": "1"}, {"groupId": "OG001", "value": "1", "spread": "1"}, {"groupId": "OG002", "value": "3", "spread": "1"}, {"groupId": "OG003", "value": "3", "spread": "1"}, {"groupId": "OG004", "value": "2", "spread": "1"}, {"groupId": "OG005", "value": "5", "spread": "1"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.3665", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1", "ciUpperLimit": "2"}, {"groupIds": ["OG001"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0357", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "3"}, {"groupIds": ["OG002"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0004", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1", "ciUpperLimit": "5"}, {"groupIds": ["OG003"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0086", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1", "ciUpperLimit": "4"}, {"groupIds": ["OG004"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.032", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "5"}, {"groupIds": ["OG005"], "groupDescription": "Placebo corrected change from baseline least squares mean +/- the standard error of the mean", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "p-value is not adjusted for multiple comparison Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis is based on the following model: CFB Parameter = Bin Group + Baseline + Error, treating patients as a random effect.", "paramType": "LSM placebo corrected diff from baseline", "paramValue": "5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3", "ciUpperLimit": "6"}, {"groupIds": ["OG000", "OG001", "OG002", "OG003", "OG004", "OG005"], "groupDescription": "All available concentration data are used in the model as a continuous variable.\n\np-value based on individual plasma concentration of CK-1827452 vs. corresponding fractional shortening PD assessment (not binned based on plasma concentration)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Threshold for statistical significance: p\\<0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA analysis based on the following model: Change from baseline = Concentration + Baseline + Error, treating patients as random effect", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "CK-1827452 Maximum Observed Plasma Concentration (Cmax)", "description": "Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nanogram/milliliter", "timeFrame": "2 days", "groups": [{"id": "OG000", "title": "Cohort 1/2: 0.125 mg/kg/h + 0.0625 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.125 mg/kg/h IV for 1 hour (loading) + 0.0625 mg/kg/h IV for 1 hour (maintenance)"}, {"id": "OG001", "title": "Cohort 1/2: 0.25 mg/kg/h + 0.125 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.25 mg/kg/h IV for 1 hour (loading) + 0.125 mg/kg/h IV for 1 hour (maintenance)"}, {"id": "OG002", "title": "Cohort 1/2: 0.5 mg/kg/h + 0.25 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.5 mg/kg/h IV for 1 hour (loading) + 0.25 mg/kg/h IV for 1 hour (maintenance)"}, {"id": "OG003", "title": "Cohort 1/2: 0.75 mg/kg/h + 0.375 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.75 mg/kg/h IV for 1 hour (loading) + 0.375 mg/kg/h IV for 1 hour (maintenance)"}, {"id": "OG004", "title": "Cohort 1/2: 1.0 mg/kg/h + 0.5 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 1.0 mg/kg/h IV for 1 hour (loading) + 0.5 mg/kg/h IV for 1 hour (maintenance)"}, {"id": "OG005", "title": "Cohort 3: 0.25 mg/kg/h + 0.025 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.25 mg/kg/h IV for 1 hour (loading) + 0.025 mg/kg/h IV for 23 hours (maintenance)"}, {"id": "OG006", "title": "Cohort 3: 0.5 mg/kg/h + 0.05 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.50 mg/kg/h IV for 1 hour (loading) + 0.05 mg/kg/h IV for 23 hours (maintenance)"}, {"id": "OG007", "title": "Cohort 3: 1.0 mg/kg/h + 0.1 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 1.0 mg/kg/h IV for 1 hour (loading) + 0.1 mg/kg/h IV for 23 hours (maintenance)"}, {"id": "OG008", "title": "Cohort 4: 0.25 mg.kg.h + 0.125 mg/kg/h + 0.025 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.25 mg/kg/h IV for 1 hour + 0.125 mg/kg/h IV for 1 hour + 0.025 mg/kg/h IV for 22 hours"}, {"id": "OG009", "title": "Cohort 4: 0.5 mg/kg/h + 0.25 mg/kg/h + 0.05 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.5 mg/kg/h IV for 1 hour + 0.25 mg/kg/h IV for 1 hour + 0.05 mg/kg/h IV for 22 hours"}, {"id": "OG010", "title": "Cohort 4: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 1.0 mg/kg/h IV for 1 hour + 0.5 mg/kg/h IV for 1 hour + 0.1 mg/kg/h IV for 22 hours"}, {"id": "OG011", "title": "Cohort 5: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 1.0 mg/kg/h IV for 1 hour + 0.5 mg/kg/h IV for 1 hour + 0.1 mg/kg/h IV for 70 hours"}, {"id": "OG012", "title": "Cohort 5: 0.75 mg/kg/h + 0.375 mg/kg/h + 0.075 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.75 mg/kg/h IV for 1 hour + 0.375 mg/kg/h IV for 1 hour + 0.075 mg/kg/h IV for 70 hours"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "9"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "10"}, {"groupId": "OG006", "value": "9"}, {"groupId": "OG007", "value": "8"}, {"groupId": "OG008", "value": "8"}, {"groupId": "OG009", "value": "9"}, {"groupId": "OG010", "value": "7"}, {"groupId": "OG011", "value": "8"}, {"groupId": "OG012", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "96.1", "spread": "27.8"}, {"groupId": "OG001", "value": "195.0", "spread": "69.4"}, {"groupId": "OG002", "value": "347.1", "spread": "108.6"}, {"groupId": "OG003", "value": "558.1", "spread": "156.5"}, {"groupId": "OG004", "value": "635.9", "spread": "158.0"}, {"groupId": "OG005", "value": "165.3", "spread": "51.4"}, {"groupId": "OG006", "value": "279.9", "spread": "55.0"}, {"groupId": "OG007", "value": "633.0", "spread": "161.5"}, {"groupId": "OG008", "value": "177.9", "spread": "103.4"}, {"groupId": "OG009", "value": "403.3", "spread": "226.2"}, {"groupId": "OG010", "value": "681.4", "spread": "159.2"}, {"groupId": "OG011", "value": "884.5", "spread": "316.2"}, {"groupId": "OG012", "value": "726.9", "spread": "62.4"}]}]}]}, {"type": "SECONDARY", "title": "CK-1827452 Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUClast)", "description": "Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hour x nanogram/milliliter", "timeFrame": "2 days", "groups": [{"id": "OG000", "title": "Cohort 1/2: 0.125 mg/kg/h + 0.0625 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.125 mg/kg/h IV for 1 hour (loading) + 0.0625 mg/kg/h IV for 1 hour (maintenance)"}, {"id": "OG001", "title": "Cohort 1/2: 0.25 mg/kg/h + 0.125 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.25 mg/kg/h IV for 1 hour (loading) + 0.125 mg/kg/h IV for 1 hour (maintenance)"}, {"id": "OG002", "title": "Cohort 1/2: 0.5 mg/kg/h + 0.25 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.5 mg/kg/h IV for 1 hour (loading) + 0.25 mg/kg/h IV for 1 hour (maintenance)"}, {"id": "OG003", "title": "Cohort 1/2: 0.75 mg/kg/h + 0.375 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.75 mg/kg/h IV for 1 hour (loading) + 0.375 mg/kg/h IV for 1 hour (maintenance)"}, {"id": "OG004", "title": "Cohort 1/2: 1.0 mg/kg/h + 0.5 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 1.0 mg/kg/h IV for 1 hour (loading) + 0.5 mg/kg/h IV for 1 hour (maintenance)"}, {"id": "OG005", "title": "Cohort 3: 0.25 mg/kg/h + 0.025 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.25 mg/kg/h IV for 1 hour (loading) + 0.025 mg/kg/h IV for 23 hours (maintenance)"}, {"id": "OG006", "title": "Cohort 3: 0.5 mg/kg/h + 0.05 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.50 mg/kg/h IV for 1 hour (loading) + 0.05 mg/kg/h IV for 23 hours (maintenance)"}, {"id": "OG007", "title": "Cohort 3: 1.0 mg/kg/h + 0.1 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 1.0 mg/kg/h IV for 1 hour (loading) + 0.1 mg/kg/h IV for 23 hours (maintenance)"}, {"id": "OG008", "title": "Cohort 4: 0.25 mg.kg.h + 0.125 mg/kg/h + 0.025 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.25 mg/kg/h IV for 1 hour + 0.125 mg/kg/h IV for 1 hour + 0.025 mg/kg/h IV for 22 hours"}, {"id": "OG009", "title": "Cohort 4: 0.5 mg/kg/h + 0.25 mg/kg/h + 0.05 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.5 mg/kg/h IV for 1 hour + 0.25 mg/kg/h IV for 1 hour + 0.05 mg/kg/h IV for 22 hours"}, {"id": "OG010", "title": "Cohort 4: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 1.0 mg/kg/h IV for 1 hour + 0.5 mg/kg/h IV for 1 hour + 0.1 mg/kg/h IV for 22 hours"}, {"id": "OG011", "title": "Cohort 5: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 1.0 mg/kg/h IV for 1 hour + 0.5 mg/kg/h IV for 1 hour + 0.1 mg/kg/h IV for 70 hours"}, {"id": "OG012", "title": "Cohort 5: 0.75 mg/kg/h + 0.375 mg/kg/h + 0.075 mg/kg/h", "description": "Subjects received the following CK-1827452 regimen: 0.75 mg/kg/h IV for 1 hour + 0.375 mg/kg/h IV for 1 hour + 0.075 mg/kg/h IV for 70 hours"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "9"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "10"}, {"groupId": "OG006", "value": "9"}, {"groupId": "OG007", "value": "8"}, {"groupId": "OG008", "value": "8"}, {"groupId": "OG009", "value": "9"}, {"groupId": "OG010", "value": "7"}, {"groupId": "OG011", "value": "8"}, {"groupId": "OG012", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1102.2", "spread": "257.6"}, {"groupId": "OG001", "value": "2314.3", "spread": "640.9"}, {"groupId": "OG002", "value": "4252.7", "spread": "1296.7"}, {"groupId": "OG003", "value": "6060.7", "spread": "1741.7"}, {"groupId": "OG004", "value": "8495.7", "spread": "3178.3"}, {"groupId": "OG005", "value": "3982.7", "spread": "1070.2"}, {"groupId": "OG006", "value": "8120.5", "spread": "2268.9"}, {"groupId": "OG007", "value": "18450.7", "spread": "4747.8"}, {"groupId": "OG008", "value": "4399.0", "spread": "1483.2"}, {"groupId": "OG009", "value": "10624.8", "spread": "5168.3"}, {"groupId": "OG010", "value": "19394.3", "spread": "4230.6"}, {"groupId": "OG011", "value": "59044.6", "spread": "17693.2"}, {"groupId": "OG012", "value": "43605.5", "spread": "3551.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "5 weeks", "description": "Participants were placed in bins based on their first hour loading dose or placebo. Because multiple dosing events occurred in all cohorts and some loading dose overlap occurs between Cohort 1 and 2 as well as between Cohort 3 and 4, participant numbers in this section do not match the numbers in the participant flow section.", "eventGroups": [{"id": "EG000", "title": "Placebo", "seriousNumAffected": 0, "seriousNumAtRisk": 41, "otherNumAffected": 8, "otherNumAtRisk": 41}, {"id": "EG001", "title": "Cohorts 1 and/or 2, Loading Dose of 0.125 mg/kg/hr", "description": "Loading dose is the first hour of IV infusion.", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 1, "otherNumAtRisk": 8}, {"id": "EG002", "title": "Cohorts 1 and/or 2, Loading Dose of 0.25 mg/kg/hr", "description": "Loading dose is the first hour of IV infusion.", "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 0, "otherNumAtRisk": 9}, {"id": "EG003", "title": "Cohorts 1 and/or 2, Loading Dose of 0.5 mg/kg/hr", "description": "Loading dose is the first hour of IV infusion.", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 1, "otherNumAtRisk": 16}, {"id": "EG004", "title": "Cohorts 1 and/or 2, Loading Dose of 1.0 mg/kg/hr", "description": "Loading dose is first hour of IV infusion.", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 4, "otherNumAtRisk": 6}, {"id": "EG005", "title": "Cohorts 1 and/or 2, Loading Dose of 0.75 mg/kg/hr", "description": "Loading dose is the first hour of IV infusion.", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 0, "otherNumAtRisk": 8}, {"id": "EG006", "title": "Cohort 2, Loading Dose of 2.2 mg/kg/hr", "description": "Loading dose is first hour of IV infusion. This dose level occurred in 1 patient due to accidental overdose.", "seriousNumAffected": 1, "seriousNumAtRisk": 1, "otherNumAffected": 1, "otherNumAtRisk": 1}, {"id": "EG007", "title": "Cohorts 3 and 4, Loading Dose of 0.25 mg/kg/hr", "description": "Loading dose is first hour of IV infusion.", "seriousNumAffected": 1, "seriousNumAtRisk": 18, "otherNumAffected": 6, "otherNumAtRisk": 18}, {"id": "EG008", "title": "Cohorts 3 and 4, Loading Dose of 0.5 mg/kg/hr", "description": "Loading dose is first hour of IV infusion.", "seriousNumAffected": 1, "seriousNumAtRisk": 18, "otherNumAffected": 4, "otherNumAtRisk": 18}, {"id": "EG009", "title": "Cohorts 3 and 4, Loading Dose of 1.0 mg/kg/hr", "description": "Loading dose is first hour of IV infusion.", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 1, "otherNumAtRisk": 16}, {"id": "EG010", "title": "Cohort 5, Loading Dose of 0.75 mg/kg/hr", "description": "Loading dose is first hour of IV infusion.", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 1, "otherNumAtRisk": 2}, {"id": "EG011", "title": "Cohort 5, Loading Dose of 1.0 mg/kg/hr", "description": "Loading dose is first hour of IV infusion.", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 2, "otherNumAtRisk": 8}], "seriousEvents": [{"term": "Non ST elevation MI in patient with drug overdose", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Septicemia in setting of diabetic foot ulcer", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}], "otherEvents": [{"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Troponin increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 2, "numAffected": 2, "numAtRisk": 8}]}, {"term": "Dizziness postural", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Dyspnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Infusion site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Sinus bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Other Adverse Event table shows treatment emergent adverse events that occurred in two or more patients. Total for Other Adverse Events is the number of patients affected by an adverse event where an adverse event occurred in two or more patients."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor intends to publish the results of the trial in collaboration with the Investigators."}, "pointOfContact": {"title": "Medical Director", "organization": "Cytokinetics, Inc.", "phone": "(650) 624-3011"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}